» Articles » PMID: 8646678

Resection Margins of 2 Versus 5 Cm for Cutaneous Malignant Melanoma with a Tumor Thickness of 0.8 to 2.0 Mm: Randomized Study by the Swedish Melanoma Study Group

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1996 May 1
PMID 8646678
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The traditional surgical treatment for primary malignant melanoma has often been a wide excision with a margin of about 5 cm. Since the risk of local recurrences is dependent on tumor thickness, thin tumors (<1 mm) have routinely been excised with a narrow margin. For thick tumors, the optimal resection margin is controversial, and can be determined only by prospective, randomized trials.

Methods: The Swedish Melanoma Study Group performed a prospective, randomized multicenter study to evaluate an excision margin of 2 versus 5 cm for patients with cutaneous malignant melanoma with tumor thickness > 0.8 and < or = 2.0 mm. The trial includes 769 patients. Patients with melanomas of the skin of the head, neck, hands, feet, or vulva were not included in the trial. In the event of an excision biopsy for diagnosis, radical surgery was completed within 6 weeks. The median follow-up time was 5.8 years for estimation of survival and 4.0 years for diagnosis of recurrent disease.

Results: No significant differences have been observed between the treatment groups regarding local or regional recurrences or survival.

Conclusions: We recommend an excision with a margin of 2 cm for cutaneous malignant melanoma with a tumor thickness > 0.8 and < or = 2.0 mm.

Citing Articles

The role of wide local excision of a primary lesion in cutaneous malignant melanoma: a retrospective analysis of its usefulness in local and general control of disease.

Nacchiero E, Giotta M, Robusto F, Metta M, Ronghi V, Elia R Melanoma Res. 2024; 34(6):519-527.

PMID: 39321036 PMC: 11524624. DOI: 10.1097/CMR.0000000000000999.


Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes.

Shannon A, Zager J, Perez M Cancers (Basel). 2024; 16(13).

PMID: 39001457 PMC: 11240680. DOI: 10.3390/cancers16132395.


Management of Localized Melanoma in the Anti-PD-1 Era.

Novis E, van Akkooi A Curr Oncol Rep. 2024; 26(8):924-933.

PMID: 38842606 PMC: 11300549. DOI: 10.1007/s11912-024-01556-z.


A Review of Contemporary Guidelines and Evidence for Wide Local Excision in Primary Cutaneous Melanoma Management.

Orme S, Moncrieff M Cancers (Basel). 2024; 16(5).

PMID: 38473257 PMC: 10930506. DOI: 10.3390/cancers16050895.


Surgical Management of Melanoma: Advances and Updates.

Santamaria-Barria J, Mammen J Curr Oncol Rep. 2022; 24(11):1425-1432.

PMID: 35657482 DOI: 10.1007/s11912-022-01289-x.